Hospital‐associated venous thromboembolism prophylaxis use by risk assessment at a large integrated health care network in Northern California
Journal of Hospital Medicine · 2024
DOI: 10.1002/jhm.13350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hospital Medicine, 2024. Verfasst von James Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Kaiser Foundation Hospitals, San Francisco, California, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Kaiser Permanente.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Hospital‐acquired venous thromboembolism (HA VTE) is a preventable complication in hospitalized patients.
Objective
We aimed to examine the use of pharmacologic prophylaxis (pPPX) and compare two risk assessment methods for HA VTE: a retrospective electronic Padua Score (ePaduaKP) and admitting clinician's choice of risk within the admission orderset (low, moderate, or high). Design, Settings and Participants We retrospectively analyzed prophylaxis orders for adult medical admissions (2013–2019) at Kaiser Permanente Northern California, excluding surgical and ICU patients. Intervention ePaduaKP was calculated for all admissions. For a subset of these admissions, clinician‐assigned HA VTE risk was extracted. Main Outcome and Measures Descriptive pPPX utilization rates between ePaduaKP and clinician‐assigned risk as well as concordance between ePaduaKP and clinician‐assigned risk.
Results
Among 849,059 encounters, 82.2% were classified as low risk by ePaduaKP, with 42.3% receiving pPPX. In the subset with clinician‐assigned risk (608,512 encounters), low and high ePaduaKP encounters were classified as moderate risk in 87.5% and 92.0% of encounters, respectively. Overall, 56.7% of encounters with moderate clinician‐assigned risk received pPPX, compared to 7.2% of encounters with low clinician‐assigned risk. pPPX use occurred in a large portion of low ePaduaKP risk encounters. Clinicians frequently assigned moderate risk to encounters at admission irrespective of their ePaduaKP risk when retrospectively examined. We hypothesize that the current orderset design may have negatively influenced clinician‐assigned risk choice as well as pPPX utilization. Future work should explore optimizing pPPX for high‐risk patients only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Internal Medicine, Kaiser Foundation Hospitals, San Francisco, California, USA.
- Department of Hematology and Oncology, The Permanente Medical Group, San Rafael, California, USA.
- Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
- Blue Shield of California, Oakland, California, USA.
- Department of Pulmonary/Critical Care, Kaiser Permanente Oakland Medical Center, Oakland, California, USA.
- Department of Hematology and Oncology, The Permanente Medical Group, San Francisco, California, USA.
ORCID-Profile: James Xu, Laura Myers
Förderung
- Kaiser Permanente
Zitieren
APA
Xu, J., Neeman, E., Thai, K. K., Mishra, P., Schlessinger, D., Clancy, H., Myers, L., Roubinian, N., Liu, V., & Liu, R. (2024). Hospital‐associated venous thromboembolism prophylaxis use by risk assessment at a large integrated health care network in Northern California. Journal of Hospital Medicine. https://doi.org/10.1002/jhm.13350
Vancouver
Xu J, Neeman E, Thai KK, Mishra P, Schlessinger D, Clancy H, et al. Hospital‐associated venous thromboembolism prophylaxis use by risk assessment at a large integrated health care network in Northern California. Journal of Hospital Medicine. 2024. doi:10.1002/jhm.13350
BibTeX
@article{Xu2024,
author = {Xu, James and Neeman, Elad and Thai, Khanh K and Mishra, Pranita and Schlessinger, David and Clancy, Heather and Myers, Laura and Roubinian, Nareg and Liu, Vincent and Liu, Raymond},
title = {Hospital‐associated venous thromboembolism prophylaxis use by risk assessment at a large integrated health care network in Northern California},
journal = {Journal of Hospital Medicine},
year = {2024},
doi = {10.1002/jhm.13350}
}
EUVIMED